These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 3653128)
1. Deleterious effects of low-dose oestrogen therapy on coronary status in patients with prostatic cancer. Henriksson P; Linde B; Edhag O Eur Heart J; 1987 Jul; 8(7):779-84. PubMed ID: 3653128 [TBL] [Abstract][Full Text] [Related]
2. Effects of oestrogen therapy and orchidectomy on coagulation and prostanoid synthesis in patients with prostatic cancer. Henriksson P; Blombäck M; Bratt G; Edhag O; Eriksson A; Vesterqvist O Med Oncol Tumor Pharmacother; 1989; 6(3):219-25. PubMed ID: 2515399 [TBL] [Abstract][Full Text] [Related]
3. Patients at high risk of cardiovascular complications in oestrogen treatment of prostatic cancer. Henriksson P; Edhag O; Eriksson A; Johansson SE Br J Urol; 1989 Feb; 63(2):186-90. PubMed ID: 2649197 [TBL] [Abstract][Full Text] [Related]
4. Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate Group. Mikkola AK; Ruutu ML; Aro JL; Rannikko SA; Salo JO Br J Urol; 1998 Jul; 82(1):63-8. PubMed ID: 9698663 [TBL] [Abstract][Full Text] [Related]
5. Orchiectomy versus oestrogen in the treatment of advanced prostatic cancer. Haapiainen R; Rannikko S; Ruutu M; Ala-Opas M; Hansson E; Juusela H; Permi J; Saarialho M; Viitanen J; Alfthan O Br J Urol; 1991 Feb; 67(2):184-7. PubMed ID: 2004233 [TBL] [Abstract][Full Text] [Related]
6. Prediction of cardiovascular complications in patients with prostatic cancer treated with estrogen. Henriksson P; Johansson SE Am J Epidemiol; 1987 Jun; 125(6):970-8. PubMed ID: 3578255 [TBL] [Abstract][Full Text] [Related]
7. Deteriorated arterial supply to the lower limb during oral oestrogen therapy of patients with prostatic carcinoma. Henriksson P; Linde B Urol Int; 1994; 53(2):74-8. PubMed ID: 7801420 [TBL] [Abstract][Full Text] [Related]
8. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Hedlund PO; Ala-Opas M; Brekkan E; Damber JE; Damber L; Hagerman I; Haukaas S; Henriksson P; Iversen P; Pousette A; Rasmussen F; Salo J; Vaage S; Varenhorst E; Scand J Urol Nephrol; 2002; 36(6):405-13. PubMed ID: 12623503 [TBL] [Abstract][Full Text] [Related]
9. Orchidectomy versus oestrogen for prostatic cancer: cardiovascular effects. Henriksson P; Edhag O Br Med J (Clin Res Ed); 1986 Aug; 293(6544):413-5. PubMed ID: 3091138 [TBL] [Abstract][Full Text] [Related]
10. Adrenocortical function in prostatic cancer patients: effects of orchidectomy or different modes of estrogen treatment on basal steroid levels and on the response to exogenous adrenocorticotropic hormone. Carlström K; Stege R Urol Int; 1990; 45(3):160-3. PubMed ID: 2161578 [TBL] [Abstract][Full Text] [Related]
11. High dose polyoestradiol phosphate with and without acetosalicylic acid versus orchiectomy in the treatment of prostatic cancer. Finnprostate Group. Aro JL; Haapiainen RK; Rannikko SA; Alfthan OS Br J Urol; 1989 May; 63(5):512-4. PubMed ID: 2659136 [TBL] [Abstract][Full Text] [Related]
12. Some effects of orchiectomy, oestrogen treatment and radiation therapy in patients with prostatic carcinoma. Tomić R Scand J Urol Nephrol Suppl; 1983; 77():1-37. PubMed ID: 6426040 [TBL] [Abstract][Full Text] [Related]
13. Comparison of primary orchiectomy with oestrogen therapy in advanced prostatic cancer. A 2-year follow-up report of a national, prospective prostatic cancer study. Haapiainen R; Rannikko S; Alfthan O Br J Urol; 1986 Oct; 58(5):528-33. PubMed ID: 3779355 [TBL] [Abstract][Full Text] [Related]
14. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study. Hedlund PO; Henriksson P Urology; 2000 Mar; 55(3):328-33. PubMed ID: 10699602 [TBL] [Abstract][Full Text] [Related]
15. Cardiovascular complications of estrogen therapy for nondisseminated prostatic carcinoma. A preliminary report from a randomized multicenter study. Lundgren R; Sundin T; Colleen S; Lindstedt E; Wadström L; Carlsson S; Hellsten S; Pompeius R; Holmquist B; Nilsson T Scand J Urol Nephrol; 1986; 20(2):101-5. PubMed ID: 3529368 [TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. Spetz AC; Hammar M; Lindberg B; Spångberg A; Varenhorst E; J Urol; 2001 Aug; 166(2):517-20. PubMed ID: 11458057 [TBL] [Abstract][Full Text] [Related]
17. Possible bone-preserving capacity of high-dose intramuscular depot estrogen as compared to orchidectomy in the treatment of patients with prostatic carcinoma. Carlström K; Stege R; Henriksson P; Grande M; Gunnarsson PO; Pousette A Prostate; 1997 May; 31(3):193-7. PubMed ID: 9167772 [TBL] [Abstract][Full Text] [Related]
18. Single drug polyestradiol phosphate therapy in prostatic cancer. Stege R; Carlström K; Collste L; Eriksson A; Henriksson P; Pousette A Am J Clin Oncol; 1988; 11 Suppl 2():S101-3. PubMed ID: 3242384 [TBL] [Abstract][Full Text] [Related]
19. Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma. Henriksson P; Blombäck M; Eriksson A; Stege R; Carlström K Br J Urol; 1990 Mar; 65(3):282-5. PubMed ID: 2110842 [TBL] [Abstract][Full Text] [Related]
20. Early results of the Finnish Multicentre Study of Prostatic Cancer (Finnprostate). Haapiainen R; Rannikko S; Ruutu M; Ala-Opas M; Aro J; Ervasti J; Hansson E; Hurme K; Juusela H; Mäkinen J Ann Chir Gynaecol; 1985; 74(6):277-83. PubMed ID: 4096480 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]